Concurrent Investment Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.44M Sell
3,725
-8
-0.2% -$2.97K 0.01% 846
2026
Q1
$1.09M Buy
3,733
+399
+12% +$131K 0.01% 839
2025
Q4
$1.17M Buy
3,334
+1,122
+51% +$379K 0.01% 762
2025
Q3
$715K Buy
2,212
+332
+18% +$103K 0.01% 774
2025
Q2
$731K Sell
1,880
-309
-14% -$124K 0.01% 705
2025
Q1
$952K Buy
2,189
+735
+51% +$295K 0.02% 559
2024
Q4
$536K Sell
1,454
-21
-1% -$8.79K 0.01% 651
2024
Q3
$767K Sell
1,475
-61
-4% -$32.6K 0.02% 526
2024
Q2
$832K Buy
1,536
+211
+16% +$112K 0.03% 477
2024
Q1
$687K Sell
1,325
-10
-0.7% -$4.97K 0.03% 464
2023
Q4
$629K Buy
+1,335
New +$617K 0.03% 436

Other funds holding ELV

Concurrent Investment Advisors's ELV Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Elevance Health (ELV) stake by 0.21% in Q2 2026, selling an estimated $2.97K and leaving 3,725 shares worth $1.44M. The position accounts for 0.01% of the portfolio, ranked #846.

Concurrent Investment Advisors first reported a position in ELV in Q4 2023 and has held it in 11 quarters since. 466 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Concurrent Investment Advisors held 3,725 shares of Elevance Health worth $1.44M as of Q2 2026.
  • Concurrent Investment Advisors sold 8 Elevance Health shares in Q2 2026, an estimated $2.97K.
  • Elevance Health made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #846 holding.
  • Concurrent Investment Advisors first reported a position in Elevance Health in Q4 2023 and has held it in 11 quarters since.
  • 466 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.